CTRI/2018/11/016404尚未招募3 期
A Randomized, Double Blind, Placebo Controlled Study Of Bacillus Coagulans Gbi 30, 6086 And Digestive Enzymes For The Treatment Of Loss Of Appetite In Hospitalized Individuals
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1)A SNAQ score greater or equal to 2
- •2)BMI less than or equal to 19 kg/m2
- •3)Patient consent
排除标准
- •1.Clinically significant eating disorder
- •2.Overweight with BMI greater or equal to 25 kg/m2
- •3.Diabetes mellitus
- •4.Laboratory parameters outside the normal range that are associated with a clinically significant cardiovascular, pulmonologic, hematologic, hepatological, metabolic, or renal disease or that interfere with interpretation of the clinical study or that require medications that are not permitted in the study protocol
- •5.Elevation of the serum transaminase levels (ALT/AST) to more than 3-times of the upper normal value
- •6.Elevation of the bilirubin and gamma-glutamyl transferase levels (GGT) to beyond the maximum normal value.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Angiotensin Therapeutic Vaccine (ATV) in Patients With Mild to Moderate HypertensioMen and women, 35-70 years old with mild to moderate Hypertension as classified by the British Hypertension Society (BHS) Guidelines - BHS-IV based on the following crietia of sitting blood pressure measured by spygomanography for patienst without diabetes or renal dysfunction:Grade 1 (mild): Systolic BP 140-159 mmHG and Diastolic BP of 90-99 mmHgGrade 2 (moderate): Systolic BP 160-179 mmHg and Diastolic BP 100-109 mmHgMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionMedDRA version: 9.1Level: PTClassification code 10020772Term: HypertensionMedDRA version: 9.1Level: PTClassification code 10042957Term: Systolic hypertensionMedDRA version: 9.1Level: PTClassification code 10012758Term: Diastolic hypertensionEUCTR2008-001001-41-GBProtherics Medicines Development Ltd, a BTG plc company
进行中（未招募）
不适用
A Randomized, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Romiplostim Treatment of Thrombocytopenia in Subjects with Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) - 20060198low or intermediate-1 risk MDSMedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2007-007258-75-ITAmgen Inc.240
已完成
不适用
Effectiveness and safety of a herbal composition to improve Aging Male SymptomsCTRI/2019/02/017506aila Neutraceuticals Pvt Ltd
招募中
3 期
A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Aerosolized JH509 in Hospitalized Adult Patients with Mild to Moderate COVID 19COVID-19 infections diseaseJPRN-jRCT2051200159Shoji Hashimoto385
已完成
不适用
A study of Cordyceps Capsules as an Add-On Therapy in patients with moderate COVID 19 InfectioCTRI/2020/09/028131Ambrosia Food Farm Co